State of Alaska Department of Revenue reduced its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 1.3% ...

Equities research analysts at Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) in a research report issued on Tuesday, MarketBeat ...

Indicated for patients with a confirmed mutation of the dystrophin gene amenable to exon 51 skipping, the drug could be used in around 13% of the disease population. Sarepta’s share price almost ...

Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is ...

Sarepta Therapeutics has followed through on ... progressive muscle degeneration due to alterations in a protein called dystrophin that helps keep muscle cells intact. The one-dose gene therapy ...

Arrowhead (ARWR) announced that the global licensing and collaboration agreement with Sarepta Therapeutics (SRPT) announced on November 26, 2024, has now closed. Closing of the transaction was ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After hours: 6 February at 5:49:33 pm GMT-5 ...

Dyne Therapeutics Inc.-5.60% $1.56B ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.